All In Biotech

Drug Trial Radar · NCT06987539

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)

A Phase 2 Open-label Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children From 2 Years to Less Than 18 Years of Age With Generalized Myasthenia Gravis (gMG)

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

15

Planned (sponsor's estimate)

Start

Jul 21, 2026

Primary completion

Mar 13, 2030

Study completion Mar 13, 2030

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
May 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objectives of this study are to characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of inebilizumab administered in pediatric participants with gMG, and to assess the safety and tolerability of inebilizumab administered in pediatric participants with gMG.

Conditions

  • Generalized Myasthenia Gravis

Interventions

  • InebilizumabDrug

    Inebilizumab will be administered IV.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Observed Concentration (Cmax) of InebilizumabTime frame: Up to Week 52
  2. Area Under the Concentration-time Curve (AUC) of InebilizumabTime frame: Up to Week 52
  3. Half-life (t1/2) of InebilizumabTime frame: Up to Week 52
  4. Clearance (CL) of InebilizumabTime frame: Up to Week 52
  5. Volume of Distribution at Steady State (Vss) of InebilizumabTime frame: Up to Week 52
  6. Change from Baseline in Cluster of Differentiation 20 (CD20)+ B-cell CountsTime frame: Baseline and Week 78
  7. Number of Participants Experiencing Treatment-emergent Adverse EventsTime frame: Up to Week 78
  8. Number of Participants Experiencing Clinically Significant Changes in Laboratory ParametersTime frame: Up to Week 78
  9. Number of Participants Experiencing Clinically Significant Changes in Vital SignsTime frame: Up to Week 78

Locations

14 sites in 8 countries. Site status is shown where the registry gives one.

  • Ann and Robert H Lurie Childrens Hospital of Chicago

    Chicago, Illinois · Recruiting

  • The Childrens Hospital of Philadelphia

    Philadelphia, Pennsylvania · Recruiting

  • Austin Neuromuscular Center

    Austin, Texas · Recruiting

  • Seattle Childrens Hospital

    Seattle, Washington · Recruiting

  • Hospital Italiano de Buenos Aires

    CABA, Buenos Aires, Argentina · Recruiting

  • Hospital Britanico de Buenos Aires

    CABA, Buenos Aires, Argentina · Recruiting

  • Hospital Santa Izabel

    Salvador, Estado de Bahia, Brazil · Recruiting

  • Instituto da Crianca - Hospital das Clinicas Fmusp

    São Paulo, São Paulo, Brazil · Recruiting

  • Hopital Armand Trousseau

    Le Kremlin-Bicêtre, France · Recruiting

  • Azienda Ospedaliera Universitaria Meyer

    Florence, Italy · Recruiting

  • Medicover Integrated Clinical Services Spolka Z Ograniczona Odpowiedzialnoscia

    Bydgoszcz, Poland · Recruiting

  • Lech Szczechowski Wielospecjalistyczna Poradnia Lekarska Synapsis

    Katowice, Poland · Recruiting

  • Hospital Universitari i Politecnic La Fe

    Valencia, Spain · Recruiting

  • John Radcliffe Hospital

    Oxford, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.